Ardelyx (ARDX) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results
March 4, 2016 6:00 AM ESTFREMONT, Calif., March 4, 2016 /PRNewswire/ --Â Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2015.
"2015 was an exceptional year for Ardelyx, highlighted by the advancement of our clinical programs and other corporate achievements," said Mike Raab, President and Chief Executive Officer of Ardelyx. "We regained worldwide rights to our lead product candidate, tenapanor, from AstraZeneca, and accelerated its development in multiple... More
